malt1

MALT1-IN-11, a potent MALT1 protease inhibitor (IC 50 < 10 nM), effectively reduces IL10 secretion, exhibiting an IC 50 between 10-100 nM. This compound is primarily utilized in the study of cancer, autoimmune, and inflammatory disorders.

MALT1-IN-3 is a potent inhibitor of MALT1 protease (IC50: 0.06 μM) with IC50 values of 0.14 and 0.13 μM for human IL6 and IL10, respectively, in OCI-LY3 cells.

MALT1-IN-8 is a potent inhibitor of MALT1 protease (IC50: 2 nM) that inhibits the growth of OCI-LY3 lymphoma cells (IC50: 1.16 μM) and exhibits anticancer activity.

MALT1-IN-14 (comp 2) acts as an inhibitor of MALT1, boasting an IC50 value of 0.081 μM.

MALT1-IN-6 is a MALT1 protease inhibitor (Ki: 9 nM) that exhibits anticancer activity.

NVS-MALT1 is an allosteric inhibitor of MALT1 [1].

MI-2 (MALT1 inhibitor) is an irreversible MALT1 inhibitor.

(R)-MALT1-IN-3 (compound 121) is a potent MALT1 protease inhibitor with an IC50 of 20 nM, and demonstrates IC50 values of 60 nM and 40 nM for human IL6 and IL10, respectively, in OCI-LY3 cells.

(R)-MALT1-IN-7 (compound 142a) is a potent MALT1 protease inhibitor with potential applications in cancer research.

MALT1-IN-7 [compound 142b] is a potent MALT1 protease inhibitor with potential applications in cancer research.

(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease, capable of inhibiting MALT1 activity and potentially mitigating the enhancement of MALT1 activity due to abnormal T-cell or B-cell receptor signaling, cancer, or inflammatory diseases. It has potential for studies related to MALT1-related diseases.

MALT1-IN-5 is a potent inhibitor of the MALT1 protease and can be used in cancer research.

MALT1-IN-9 (WO2021000855A1, Compound 5), a highly potent inhibitor of MALT1 protease, demonstrates an IC50 value of <500 nM when tested in Raji MALT1-GloSensor cells. MALT1-IN-9 exhibits significant anticancer properties [1].

Mepazine (Pecazine) is a potent and selective inhibitor of MALT1, inhibiting GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM, respectively. Mepazine enhances apoptosis and impacts cell viability.

MLT-943 is a potent, selective, and orally active MALT1 protease inhibitor [1].

Irreversible MALT1 inhibitor. Suppresses T cell activation-induced cleavage of Bcl-10 in a dose-dependent manor. Reduces Jurkat cell adhesion to fibronectin. Cell permeable.

Mepazine hydrochloride monohydrate is a MALT1 inhibitor.

MLT-231, a potent and highly selective allosteric MALT1 inhibitor, has an IC50 of 9 nM and specifically inhibits endogenous BCL10 cleavage with an IC50 of 160 nM. It exhibits antitumor activity in an ABC-DLBCL type xenograft mouse model[1].

MLT-748 is a MALT1 allosteric inhibitor that inhibits the growth of lung cancer cells. MLT-748 acts by blocking the protein hydrolyzing activity of MALT1.

Z-VRPR-FMK, an irreversible inhibitor of the MALT1 protein, effectively suppresses the proliferation and invasion of diffuse large B-cell lymphoma. This is achieved through the inhibition of MALT1-induced NF-κB activation and MMP (matrix metalloproteinase) expression.

Safimaltib is an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and exhibits antitumor activity.

SGR-1505, an orally active MALT1 allosteric inhibitor, reduces MALT1 enzymatic activity and demonstrates anti-proliferative effects in both BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 is applicable for B-cell lymphoma research [1].

MLT-747 is an effective and allosteric inhibitor of MALT1. It binds MALT1 in the allosteric Trp580 pocket (IC50: 14 nM).

MLT-985, a highly selective allosteric MALT1 inhibitor, exhibits an IC50 value of 3 nM.